What is MobileODT?
Founded in 2012 and headquartered in Tel Aviv, Israel, MobileODT is at the forefront of developing advanced AI colposcopy and visual assessment technologies. Their solutions aim to empower women's health clinicians with more accurate and efficient diagnostic tools, thereby improving patient outcomes and access to care. The company's focus on leveraging artificial intelligence for critical medical assessments positions it as a key innovator in the digital health landscape. The enterprise-level backing suggests a strong validation of its technology and business model by sophisticated investors.
How much funding has MobileODT raised?
MobileODT has raised a total of $10.8M across 2 funding rounds:
Series B
$6.8M
Series C
$4M
Series B (2017): $6.9M with participation from OrbiMed Advisors LLC and Tristel
Series C (2020): $4M led by Tristel, Tara Health, OrbiMed Israel Partners, and Laerdal
Key Investors in MobileODT
OrbiMed Israel Partners
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains. The firm manages capital across biopharmaceuticals, medical devices, digital health platforms, diagnostics, and healthcare services, bringing together investment professionals with extensive experience in life sciences and healthcare business development.
Tristel
Tristel is a company involved in the healthcare sector, with its domain suggesting a focus on medical devices or related services. Its participation in MobileODT's funding rounds indicates a strategic interest in the advancement of women's health technology and AI-driven diagnostic solutions.
Tara Health
Tara Health is an investor that has participated in MobileODT's funding rounds. While specific details about its investment focus are not provided, its involvement suggests a commitment to companies innovating within the healthcare and technology sectors, particularly those with a social impact.
What's next for MobileODT?
With the recent major strategic investment, MobileODT is poised for accelerated growth and further innovation. This capital infusion is expected to fuel the expansion of its AI-powered diagnostic platforms, enhance its market reach, and potentially drive the development of new clinical applications. The company's strategic focus on women's health, combined with its technological prowess, positions it to address significant unmet needs in global healthcare. Future developments may include broader clinical adoption, strategic partnerships, and continued refinement of its AI algorithms to maintain its competitive edge in the rapidly evolving health tech industry.
See full MobileODT company page
